ELYMBI
Dead / Abandoned — Abandoned — after publication (as of 28 Aug 2025)
What this means for you
This application is over — abandoned 27 Aug 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98771024
- Mark type
- Stylized text
- Filed
- 26 Sept 2024
- Published for opposition
- 24 Jun 2025
- Abandoned
- 27 Aug 2025
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations for gene therapy, gene editing, and genome editing for treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Gene therapies, in the nature of pharmaceuticals, for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations containing viral vectors for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
- Class 041 — Education and entertainment services: Medical training and teaching
- Class 044 — Medical, beauty and agricultural services: Medical services; providing health information
Owner
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 22 Oct 2025 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 03 Sept 2025 — ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
- 28 Aug 2025 — ABANDONMENT - AFTER PUBLICATION
- 27 Aug 2025 — TEAS EXPRESS ABANDONMENT RECEIVED
- 22 Jul 2025 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 24 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Jun 2025 — PUBLISHED FOR OPPOSITION
- 18 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 May 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 May 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 22 May 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 19 Apr 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 19 Apr 2025 — NON-FINAL ACTION E-MAILED
- 19 Apr 2025 — NON-FINAL ACTION WRITTEN